Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to untangle two similar brain diseases

NCT ID NCT07304960

First seen Jan 04, 2026 · Last updated Jun 20, 2026 · Updated 33 times

Summary

This study will compare 100 people with either multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) to find better ways to tell them apart. Researchers will measure specific proteins in the blood and look at MRI scans. The goal is to improve diagnosis and management for these often-confused conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MS (MULTIPLE SCLEROSIS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors better distinguish between MS and NMOSD, leading to more accurate diagnoses and tailored treatments.

What could go wrong

This is an observational study, not a treatment trial. It will not directly test any new therapy, and results may not change current practice immediately.

Conditions

The condition(s) this trial relates to.

multiple sclerosis neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.